Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Autoantibodies and autoimmune disease during treatment of children with chronic hepatitis C.

Molleston JP, Mellman W, Narkewicz MR, Balistreri WF, Gonzalez-Peralta RP, Jonas MM, Lobritto SJ, Mohan P, Murray KF, Njoku D, Rosenthal P, Barton BA, Talor MV, Cheng I, Schwarz KB, Haber BA; PEDS-C Clinical Research Network.

J Pediatr Gastroenterol Nutr. 2013 Mar;56(3):304-10. doi: 10.1097/MPG.0b013e3182774cae.

2.

Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis.

Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, Mills EJ.

Clin Infect Dis. 2013 Apr;56(7):961-7. doi: 10.1093/cid/cis1031. Epub 2012 Dec 12. Review.

3.

L11. Hepatitis C virus mixed cryoglobulinemia vasculitis: therapeutic options.

Cacoub P, Terrier B, Saadoun D.

Presse Med. 2013 Apr;42(4 Pt 2):523-7. doi: 10.1016/j.lpm.2013.01.011. Epub 2013 Feb 28. Review. No abstract available.

PMID:
23453499
4.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

5.

[Chronic hepatitis C: improved cure rates with new approved medications].

Grammatikos G, Vermehren J, Zeuzem S.

MMW Fortschr Med. 2012 Jun 21;O 154 Suppl 2:65-9; quiz 70. Review. German. No abstract available.

PMID:
22916428
6.

Type B insulin resistance developing during interferon-alpha therapy.

Daniel AL, Houlihan JL, Blum JS, Walsh JP.

Endocr Pract. 2009 Mar;15(2):153-7. Review.

7.

Interferon therapy in hepatitis C leading to chronic type 1 diabetes.

Zornitzki T, Malnick S, Lysyy L, Knobler H.

World J Gastroenterol. 2015 Jan 7;21(1):233-9. doi: 10.3748/wjg.v21.i1.233. Review.

8.
9.

Hepatitis C virus and type 1 diabetes.

Fallahi P, Di Domenicantonio A, Mazzi V, Santini F, Fabiani S, Sebastiani M, Zignego AL, Ferri C, Antonelli A.

Clin Ter. 2013;164(5):e437-44. doi: 10.7417/CT.2013.1624. Review.

PMID:
24217846
10.

Autoantibodies in chronic hepatitis C: A clinical perspective.

Narciso-Schiavon JL, Schiavon Lde L.

World J Hepatol. 2015 May 18;7(8):1074-85. doi: 10.4254/wjh.v7.i8.1074. Review.

11.

Autoantibodies in liver disease: important clues for the diagnosis, disease activity and prognosis.

Himoto T, Nishioka M.

Auto Immun Highlights. 2013 Feb 22;4(2):39-53. doi: 10.1007/s13317-013-0046-7. eCollection 2013 Aug. Review.

12.

Autoantibodies and depression: evidence for a causal link?

Iseme RA, McEvoy M, Kelly B, Agnew L, Attia J, Walker FR.

Neurosci Biobehav Rev. 2014 Mar;40:62-79. doi: 10.1016/j.neubiorev.2014.01.008. Epub 2014 Jan 27. Review.

PMID:
24480318
13.

Metformin - The Drug for the Treatment of Autoimmune Diseases; A New Use of a Known Anti-Diabetic Drug.

Tomczynska M, Bijak M, Saluk J.

Curr Top Med Chem. 2016;16(19):2223-30. Review.

PMID:
26881720
Items per page

Supplemental Content

Write to the Help Desk